Endogenous 6-Hydroxymelatonin Excretion and Subsequent Risk of Breast Cancer: A Prospective Study
Annual rept. 1 Mar 2004-28 Feb 2005
STATE UNIV OF NEW YORK AT BUFFALO AMHERST
Pagination or Media Count:
The prevalence of breast cancer is greatest in industrialized regions and exposure to light at night has been proposed as a potential risk factor. Modulation of melatonin secretion by light has been implicated in the caupathway linking exposure to light and breast cancer risk. Recent evidence indicates that melatonin is a naturaoncostatic agent capable of functioning through a variety of anti-proliferative anti-oxidative and immunostimulatory mechanisms. We conduct a study to investigate the association of prediagnostic melatonproduction and subsequent breast cancer risk in a prospective cohort study, the Italian ORDET study. Thus, prediagnostic melatonin production will be measured as urine levels of the 6-hydroxymelatonin sulphate 6-OHMS, its primary enzymatic metabolite, in 12-hour urine overnight collection. The study will be conducas a nested case-control study. We expect 533 breast cancer cases among cohort members during the 17 year follow-up period. Four controls will be matched to each case on age, menopausal status, recruitment center a time of recruitment for a total number of 2,132 control subjects. This study would be the first one analyzing potential effect of melatonin on breast cancer risk. It will provide important data on risk factors that are likely key to the development of this disease at great public health impact.
- Anatomy and Physiology
- Medicine and Medical Research